Erythro-9-(2-hydroxy-3-nonyl) Adenine alone and in combination with 9-beta-D-arabinofuranosyladenine in treatment of systemic herpesvirus infections in mice.
Although the antiviral activity of erythro-9-(2-hydroxy-3-nonyl)adenine, a potent adenosine deaminase inhibitor, against herpes simplex virus type 1 in cell culture was readily confirmed, the compound was found to be totally ineffective in the treatment of experimentally induced systemic herpes simplex virus type 1 infections in Swiss mice. Data were obtained, however, which clearly indicated that the antiviral potency of 9-beta-D-arabinofuranosyladenine in vivo could be enhanced by the co-administration of low, nontoxic doses of erythro-9-(2-hydroxy-3-nonyl)adenine.
D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D058892:Adenosine Deaminase Inhibitors; D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D006561:Herpes Simplex / Q000188:drug therapy*; D051379:Mice; D009700:Nucleoside Deaminases / Q000037:antagonists & inhibitors*; D018139:Simplexvirus / Q000187:drug effects; D014740:Vidarabine / Q000008:administration & dosage*
D058892:Adenosine Deaminase Inhibitors; D000998:Antiviral Agents; C010192:9-(2-hydroxy-3-nonyl)adenine; D009700:Nucleoside Deaminases; D014740:Vidarabine; D000225:Adenine